Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Achieving antigen-specific immune regulation.

Kevan C Herold1

  • 1Naomi Berrie Diabetes Center, Division of Endocrinology and Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA. kh318@columbia.edu

The Journal of Clinical Investigation
|February 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A surviving beta cell subpopulation enriched in patients with T1D.

bioRxiv : the preprint server for biology·2026
Same author

New and emerging therapies in type 1 diabetes mellitus.

The Journal of clinical investigation·2026
Same author

Tet2 modulates ER stress responses related to β-cell death and autoimmunity in diabetes.

iScience·2026
Same author

Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations.

The Journal of clinical investigation·2026
Same author

Anti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes.

JCI insight·2026
Same author

Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes.

Diabetes·2026
Same journal

Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

The Journal of clinical investigation·2026
Same journal

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

The Journal of clinical investigation·2026
Same journal

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

The Journal of clinical investigation·2026
Same journal

MDM2 degraders for Merkel cell carcinoma: round peg in a round hole.

The Journal of clinical investigation·2026
Same journal

Ammonia in the crosshairs: microbial targets for metabolic dysfunction-associated steatohepatitis prevention.

The Journal of clinical investigation·2026
Same journal

Molecular mechanisms regulating cGAS/STING activation in health and disease.

The Journal of clinical investigation·2026
See all related articles

Patients with diabetes exhibit a pro-inflammatory T cell response to self-antigens, producing IFN-gamma. In contrast, healthy individuals produce the regulatory cytokine IL-10, suggesting a potential mechanism for controlling autoimmunity.

Area of Science:

  • Immunology
  • Autoimmunity
  • Diabetes Research

Background:

  • Investigates T cell responses to autoantigens in diabetes patients versus healthy controls.
  • Focuses on cytokine production (IFN-gamma and IL-10) following antigen presentation.

Discussion:

  • Highlights the contrasting immune profiles in diabetes patients and normal subjects.
  • Suggests a potential regulatory mechanism for autoimmunity initiated during antigen presentation.

Key Insights:

  • Diabetes patients' T cells produce IFN-gamma in response to normal protein peptides.
  • Normal subjects' T cells produce IL-10 to the same autoantigens.
  • IL-10 production indicates a potential natural control of autoimmunity.

Outlook:

Related Experiment Videos

  • Further research into IL-10's role could reveal new therapeutic targets for autoimmune diseases.
  • Understanding these differential responses may lead to personalized diabetes treatments.
  • This finding opens avenues for exploring antigen-specific immunotherapy.